百诚医药：与浙江众神创新医药科技签署《技术开发合作协议》

Core Viewpoint - The company has entered into an exclusive licensing agreement with Zhejiang Zhongshen Innovative Pharmaceutical Technology Co., Ltd. for the innovative drug BIOS-0629 in the Greater China region, with a transaction price of RMB 300 million [1] Group 1: Agreement Details - The collaboration includes a technical development cooperation agreement and a supplementary agreement, which will take effect after approval from the company's shareholders' meeting [1] - The transaction constitutes a related party transaction as Feng Enguang, the legal representative and senior management of Zhongshen Innovation, was previously the company's vice president [1]